Sysmex Inostics
Dr. Kimberly Nickel currently serves as a Scientific Project Manager at Sysmex Inostics since April 2022. Prior experience includes a role as Managerin at CIPOC GmbH from June 2019 to March 2022, and as a Doktorandin at Beiersdorf between December 2015 and May 2019. Dr. Nickel earned a Ph.D. in Biochemistry from Leibniz Universität Hannover, completing studies in December 2021, and holds a Master of Science in Molecular Life Sciences from the University of Hamburg, where studies were completed in September 2015.
This person is not in any offices
Sysmex Inostics
Leaders of the Global Liquid Biopsy Revolution As pioneers in blood-based cell-free tumor DNA (ctDNA) mutation detection, Sysmex Inostics has provided custom assays and CLIA-certified lab services to leading BioPharma companies over the last 10 years with the overall goal: to develop therapeutics that extend lives and provide diagnostics to monitor response to therapy, identify targetable resistance alterations, and detect minimal residual disease (MRD). SafeSEQ NGS technology can detect clinically relevant mutations in circulating tumor DNA (ctDNA) with robust detection as low as 0.03% mutant allele frequency (MAF), thus ensuring reliable molecular information for real-time therapy selection as well as monitoring of tumor response from across a broader range of genomic regions.